Goldman Sachs previews India CRO/CDMO meetings, focusing on validating the 4Cs: CDMO, CRO, Costs, Capex

Overview

This is a preview report on the India CRO/CDMO industry. Goldman Sachs plans to host an India CRDMO itinerary in Bangalore and Hyderabad from June 10 to 12, 2026, with about 10 participating companies. Rather than being a full earnings forecast update, the report centers on a checklist of key questions ahead of management meetings to help investors validate industry demand, order quality, capacity utilization, cost pressures, and capital expenditure returns.

Core views

The core view is that India’s CRO/CDMO sector is at an important inflection point: on one hand, CDMO saw improvement in the seasonally stronger Q4, while China+1, GLP-1, ADC, HPAAPI, and complex chemistry capabilities may bring structural opportunities; on the other hand, slower FY26 operating profit growth, ramp-up of facility commercialization, customer and molecule concentration, ARV pricing pressure, and the payback cycle of elevated capex still require further explanation from management.

Analysis framework

The report adopts a management diligence question framework rather than a single valuation model. The analysis focuses by company on commercial molecule pipelines, order books, customer mix, capacity utilization, EBITDA break-even, deleveraging, RoCE, and capital allocation over the next 24-36 months, while linking company differences through the industry-wide 4Cs.

Methodology notes

• Management due diligence framework4Cs：CDMO/CRO/Costs/Capex

  Use four industry questions to assess India CRDMO companies in a unified way

  CDMO focuses on whether growth is sustainable and FY27 inventory for key commercial products; CRO focuses on contract research services, headcount expansion, and AI usage; Costs focuses on profit pressure from the ramp-up of new commercial facilities; Capex focuses on when the investments of the past two years will convert into revenue.

• Equity factor frameworkGS Factor Profile

  Growth, Financial Returns, Multiple, and Integrated

  Goldman Sachs uses normalized rankings of growth, financial returns, and valuation multiples to compare stocks relative to the market and peers, while the Integrated metric combines growth, returns, and valuation.

• Trading scenario frameworkM&A Rank

  Acquisition probability tiers

  Goldman Sachs classifies covered companies into three tiers by potential acquisition likelihood: 1 indicates high probability, 2 indicates medium probability, and 3 indicates low probability; M&A components may be included in target prices for tier 1 or 2 names.

• Data toolQuantum

  Goldman Sachs proprietary financial database

  Quantum is used to view detailed financial history, forecasts, and ratios, supporting deep single-company analysis or cross-company comparison.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Syngene International

  Covered company, Buy

  Strengths

  An integrated CRAMS/CRDMO platform spanning drug research, development, and manufacturing, and operating dedicated centers for global innovative pharma companies such as BMS, Amgen, and Baxter.

  Weaknesses

  Discovery Services growth has lagged, and the revenue ramp-up and EBITDA break-even of the integrated Stelis biologics facility still need validation.

  Comparison

  Compared with other India CRDMO companies, Syngene has a higher share of CRO revenue and stronger customer quality, but it also needs more proof of CRO recovery and CDMO commercialization conversion.

  Risks

  China+1 demand may remain at the RFP or exploratory discussion stage, while global CRO pricing pressure and insufficient biologics facility utilization could weigh on profits.

• Neuland Labs

  Covered company, Buy

  Strengths

  Strong API and CMS capabilities, with 3 manufacturing facilities near Hyderabad, 1,226KL of combined capacity, and an R&D team of 311 people, as well as a dedicated laboratory in peptides.

  Weaknesses

  The CMS business can be volatile, and revenue may face concentration risk in top commercial molecules.

  Comparison

  Compared with integrated platforms, Neuland is more focused on chemistry and custom manufacturing, with GLP-1, peptide, and China+1 pipelines as key differentiated validation points.

  Risks

  Limited visibility on the top five commercial molecules before FY27, slow customer validation, or technical bottlenecks in capacity could constrain growth.

• TheraNym Bio / Aurobindo Pharma

  TheraNym Bio is an Aurobindo-related entity; Aurobindo Pharma is a covered company rated Buy

  Strengths

  Building integrated bio CDMO capabilities for US biopharma clients and has signed a biologics CDMO product manufacturing agreement with MSD.

  Weaknesses

  Capacity expansion and project commercialization are still at the validation stage, and the ramp from 30KL to 60KL requires order and funding support.

  Comparison

  Compared with mature small-molecule CDMOs, TheraNym Bio is more focused on biologics CDMO expansion, offering higher potential upside but also higher execution risk.

  Risks

  Funding runway, burn rate, clinical or regulatory milestones, and unclear partnership commercialization models could all affect valuation recognition.

• Laurus Labs

  Covered company, Sell

  Strengths

  A vertically integrated pharma and biopharma platform with about 15 facilities, 9 of which are for CDMO, and is transitioning from ARV/API toward non-ARV and CDMO businesses.

  Weaknesses

  More than 60% of FY26 revenue still comes from generics, the ARV business faces pricing pressure, and new businesses such as Laurus Bio and animal health absorb significant capex.

  Comparison

  Compared with purer CRDMO companies, Laurus is still weighed down by traditional generics and ARV businesses, making transformation visibility the key differentiator.

  Risks

  The bottoming of ARV prices is uncertain, CDMO order book transparency is limited, and the path to EBITDA break-even in biologics and animal health may be slower than expected.

• Piramal Pharma

  Covered company, Buy

  Strengths

  Owns PPS, PCC, and the India consumer healthcare business, with 15 global facilities covering development, manufacturing, complex hospital generics, and consumer health.

  Weaknesses

  Margins in Complex Hospital Generics are volatile, net debt remains elevated, and the CDMO business needs to fill the Rimegepant gap.

  Comparison

  Piramal is more global and diversified than a single India CDMO company, but its asset mix is more complex, making deleveraging and business quality divergence more important.

  Risks

  The CDMO pipeline may be insufficient to offset product gaps, CHG margin normalization may underdeliver, and monetization of non-core assets or deleveraging progress may be slow.

• Cohance Lifesciences

  Covered company, Buy

  Strengths

  A large pure-play India CRAMS/CDMO company, with four major businesses including Pharma CDMO, Specialty Chemicals CDMO, API, and Formulations; ADC, HPAAPI, and oligos capabilities provide differentiation.

  Weaknesses

  Revenue and cost synergies after the Suven-Cohance merger still need to be delivered consistently, and the capital allocation path needs monitoring.

  Comparison

  Compared with platform peers, Cohance is more distinctive in later-stage and commercial molecules, relationships with top-20 innovative pharma customers, and high-end capabilities.

  Risks

  Integration falling short of the original investment case, excessive M&A or capex under Advent’s backing, or limited order visibility could affect returns.

• Anthem Bio

  Not Covered

  Strengths

  A one-stop CRDMO positioned across small molecules, biologics, and complex fermentation products, with over 550 customers across 44+ countries and an EBITDA margin of about 35%+.

  Weaknesses

  Expansion of Unit III and FY26-FY28E capex need to convert into revenue, and whether high margins can be maintained after scaling still needs validation.

  Comparison

  Anthem is relatively differentiated in fermentation, complex chemistry, GLP-1 peptide intermediates, and specialty ingredients.

  Risks

  Shifts in business mix among CRDMO, specialty ingredients, and fermentation products may compress margins, and returns on capacity expansion remain uncertain.

• Sai Life Sciences

  Not Covered

  Strengths

  An integrated CRDMO platform serving global innovative pharma and biotech customers, with 170+ active NCE projects and R&D footprints across East and West including Hyderabad, Manchester, and Boston.

  Weaknesses

  The path to improving working capital intensity and RoCE requires explanation from management, and the pace of conversion of commercial projects is key.

  Comparison

  Compared with other India CDMOs, Sai has a more pronounced innovator-pharma and NCE customer mix, and the conversion of later-stage pipelines into commercialization is central to valuation.

  Risks

  Phase III and commercial molecule launch timing may fall short of expectations, changes in the CRO/CDMO mix may affect margins, and utilization of Bidar expansion may be insufficient.

• Blue Jet Healthcare

  Not Covered

  Strengths

  Holds niche-leading positions in contrast media intermediates, high-intensity sweeteners, and pharma CDMO/contract manufacturing, with a high share of regulated-market revenue and a debt-free balance sheet.

  Weaknesses

  CDMO/contract manufacturing customers are concentrated among a small number of large innovator clients, and new blocks capex needs to prove asset turns and incremental RoCE.

  Comparison

  Blue Jet is more like a niche high-margin intermediates supplier than a full-chain CRDMO platform, with its core strengths in barriers and customer stickiness in contrast media intermediates.

  Risks

  Intensifying competition from Chinese players and Divi's, weaker sustainability of iohexol/contrast media pricing, and Bempedoic acid intermediates contracts coming in below expectations.

• Vimta Labs

  Not Covered

  Strengths

  A mature India CRO and analytical testing service provider covering clinical reference labs, pharmaceutical analytical testing, BA-BE, preclinical/toxicology, and food-water-environment testing, with broad regulatory certifications.

  Weaknesses

  Structural slowdown in clinical research and bioequivalence businesses, with a model that is more asset- and scientific-talent-intensive.

  Comparison

  Unlike manufacturing-oriented CDMO companies, Vimta is more focused on testing, clinical, and preclinical services, with a more diversified revenue mix.

  Risks

  US FDA inspection cycles may affect growth recovery, ramp-up of new capacity in Genome Valley may be slow, and shifts in the mix between food-water testing and pharma testing may affect long-term margins.

Key data

• Report date2026-06-08, 2:26PM ISTFrom the report header.
• Roadshow itineraryJune 10-12, 2026, 1 day in Bangalore and 2 days in HyderabadThe itinerary is intended to gather frontline feedback from India CRDMO companies.
• Participation scopeAbout 10 India CRO/CDMO listed companies, 6 of which are covered by Goldman SachsThe report emphasizes that the meetings cover core companies in the India CRDMO industry.
• Four core topicsCDMO, CRO, Costs, CapexThese are the 4Cs investors have focused on most recently.
• Industry profit signalSlower FY26 operating profit growthThe chart title indicates that operating profit growth for covered companies is slowing in FY26.
• Syngene revenue mixCRO accounts for about 3/5 of revenue, CDMO about 2/5; discovery CRO accounts for 55-60% of revenueManagement questions focus on ramp-up of the Stelis biologics facility, China+1 conversion, and recovery in Discovery Services.
• Neuland Labs commercial molecules19 molecules already commercialized, with another 7 in pre-registration/registration stageCMS revenue is about 60%, versus 14% in FY19.
• TheraNym Bio capacity planInitial 30KL, planned to double to 60KL; originally planned capex of about US$125mnThe MSD-related bio CDMO project is a key validation item.
• Piramal Pharma platform15 global facilities, with a distribution network covering more than 100 countriesBusinesses include PPS, PCC, and the India consumer healthcare business.
• Cohance Life Sciences scale21 facilities with combined capacity of 3,000+kL; around 70-80% of revenue from the US and EuropeADC, HPAAPI, and oligos are differentiated capabilities.
• Anthem Bio customers and margin550+ customers across 44+ countries; EBITDA margin about 35%+The market is focused on FY26-FY28E capex and the sustainability of high margins.
• Sai Life Sciences project base10 global top-20 pharma customers, 280+ innovator customers, 170+ active NCE projectsAbout 80%+ of revenue comes from regulated markets.
• Blue Jet regional mix and profitabilityRegulated-market revenue accounts for about 75-80%, EBITDA margin about 35%+, debt-free balance sheetKey questions focus on competition in contrast media intermediates and customer concentration.
• Vimta Labs marginEBITDA margin about 25-30%, relatively light debtFocus is on slower growth in clinical research/BA-BE, FDA inspections, and utilization of new capacity.

Impact & implications

For investors, the significance of this roadshow is in turning industry narratives into verifiable questions: if management can demonstrate that orders are shifting from exploratory discussions to long-term contracts, while capacity utilization improves and capex returns become clearer, the structural growth case for India’s CRDMO sector will gain stronger support; if feedback instead points to concentrated commercial molecules, greater pricing pressure, or more severe cost ramp-up, intra-sector divergence and downside earnings revision risk may widen.

Risks

• This report is a meeting preview, and the management questions themselves do not equate to confirmed orders, contracts, or earnings forecasts.
• China+1 demand may be only inquiries or exploratory discussions and may not convert into RFP wins and long-term contracts.
• The ramp-up of new commercial facilities may lead to costs coming first, with EBITDA break-even occurring later than the market expects.
• ARV, CRO, and some CDMO services may face global competition and pricing pressure.
• Concentration in customers, commercial molecules, or a small number of large contracts may cause revenue volatility.
• High capex, net debt, working capital, and RoCE pressure may weaken valuation flexibility.
• Regulatory inspections or approval timing from agencies such as USFDA, EMA, and PMDA may affect capacity utilization and project conversion.
• Changes in the biotech funding environment and in how AI is used may alter the CRO demand structure.

What to watch

• During the June 10-12 management meetings, whether the Q4 improvement in CDMO is sustainable and inventory levels of key FY27 products.
• Whether headcount expansion, AI usage, and improved funding conditions on the CRO side are truly driving growth in contract research services.
• Whether China+1 is converting from discussion into RFP wins, long-term contracts, and commercial orders.
• The ramp-up pace of capacities such as Stelis, Laurus Bio, Anthem Unit III, Sai Bidar, Blue Jet new blocks, and Vimta Genome Valley.
• Order visibility for GLP-1, peptide, ADC, HPAAPI, oligos, and complex chemistry capabilities.
• Piramal deleveraging, Cohance integration synergies, Laurus ARV bottoming, and changes in Blue Jet customer concentration.
• Whether FY26-FY28E revenue growth, EBITDA margins, asset turns, and RoCE match capex intensity.